HRD has become a new target for metastatic cancers, which indicates the necessity of confirming the status of HRD-related genes [59,60,61,62,63], with ARID1A, ATM, ATRX, PALB2, BARD1, RAD51C and CHEK2 being the HRD-related genes for which simultaneous examination as part of panel testing has been shown to be more suitable [64,65]. This evidence concerns the gene TBCE and metastatic malignant neoplasm.